Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology, Multinationals Dominate Japan 2017 Approvals

It was another busy year for Japanese regulators, who approved 38 new drugs in the fiscal year up to the end of this March, roughly maintaining the pace of the the previous 12 months and bringing some important new therapies to patients. New products for oncology and biologics featured heavily, with foreign multinationals dominating the list.

Japan Approvals Regulation

Innovation Critical As Japan Pharma Faces Continued Pricing Pressures

Major Japanese pharma companies will add an estimated net $6.6bn in revenues through products launched over the 10-year period to 2027 to generate a combined total of $69.5bn, although average growth will be low, constrained mainly by pricing factors at home.

Japan Business Strategies Commercial
Advertisement
UsernamePublicRestriction

Register

Advertisement